Jacobs Levy Equity Management
AKYA

Jacobs Levy Equity Management’s Akoya BioSciences AKYA Stock Holding History

Jacobs Levy Equity Management’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-55,801
Closed -$259K – 966
2023
Q3 		$259K Sell
55,801
-120,113
-68% -$690K ﹤0.01% 892
2023
Q2 		$1.3M Buy
+175,914
New +$1.17M 0.01% 650

Other funds holding AKYA

BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's AKYA Position: Q4 2023 in Review

Jacobs Levy Equity Management sold out of Akoya BioSciences (AKYA) in Q4 2023, closing a stake of 55,801 shares — an estimated $259K sold.

Jacobs Levy Equity Management first reported a position in AKYA in Q2 2023 and held it in 2 quarters. The position peaked at $1.3M in Q2 2023. 65 funds tracked by Wall St. Rank hold AKYA as of Q4 2023.

  • Jacobs Levy Equity Management reported no remaining Akoya BioSciences position as of Q4 2023 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 55,801 Akoya BioSciences shares in Q4 2023, an estimated $259K.
  • Jacobs Levy Equity Management first reported a position in Akoya BioSciences in Q2 2023 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Akoya BioSciences position peaked at $1.3M in Q2 2023.
  • 65 funds tracked by Wall St. Rank held Akoya BioSciences as of Q4 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2023, filed 14 Feb 2024.